Anti-CD70 (Vorsetuzumab biosimilar)

Human IgG1 monoclonal antibody (mAb) against human CD70

Anti-hCD70 mAb functions in cancer
(click to enlarge)

InvivoGen provides Anti-hCD70-hIgG1, the biosimilar of the clinical antibody vorsetuzumab. It features:

• the variable region of vorsetuzumab targeting the human cluster of differentiation 70 (hCD70)
• the IgG1 constant region of vorsetuzumab mediating high effector functions

InvivoGen's Anti-hCD70-hIgG1 was generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography. Each lot is functionally tested by flow cytometry and cellular assays (see figures).

Key features of the Anti-hCD70-hIgG1 

• Clinically-relevant variable region targeting human CD70 (vorsetuzumab)
• Human IgG1 constant region for high effector functions
• Functionally validated by flow cytometry and ADCC assay
• The absence of bacterial contamination has been confirmed

Background

Vorsetuzumab is a humanized IgG1 mAb targeting the immune checkpoint (IC) molecule CD70 (aka CD27 ligand or CD27L). This mAb can kill tumor cells through antibody-dependent cell-mediated responses (ADCC & ADCP). In addition, vorsetuzumab can also be conjugated with small molecular antitumor drugs to form a new type of targeted therapeutic molecule called antibody-drug conjugates (ADCs) with accurate targeting and greater lethality [1].  Currently, a non-fucosylated version of this mAb (SEA-CD70) is undergoing clinical evaluation in a phase I study in patients with myeloid malignancies (NCT04227847) [2]. In the appropriate context of T cell receptor engagement, the interaction of CD27 with its ligand CD70 (also known as CD27L) promotes T cell activation, maturation of effector capacity, and T cell memory [3-4]. 

 More details

References

1. Ryan MC, et al., 2010. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 24;103(5):676-84.
2. Flieswasser, T., Van den Eynde, A., Van Audenaerde, J. et al., 2022. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res 41, 12. 
3. Vitale LA, et al.,2012. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res.;18(14):3812-21.
4. Sanborn RE, et al., 2022. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer. 10(8):e005147.

Figures

Comparison of ADCC potency for native and engineered anti-human CD70 antibody isotypes. Raji-Null cells were incubated with gradient concentrations of Anti-hCD70 or Anti-β-galactosidase (β-gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with target cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

Binding of Anti-hCD70-hIgG1 mAb to hCD70. EL4 wildtype (WT) and EL4-hCD70 cells were incubated for 30 minutes with 250 ng of Anti-hCD70-hIgG1. Subsequently, a secondary PE-labeled antibody was added and incubated at room temperature for 30 minutes. The binding affinity was assessed using flow cytometry.

Specifications

Specificity: Targets cells expressing human CD70

Clonality: Monoclonal antibodies

Clone: Vorsetuzumab (Anti-hCD70-hIgG1, kappa)

Isotype: Human IgG1

Control: Human IgG1

Source: Chinese hamster ovary (CHO) cells 

Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.

Tested Applications: Flow cytometry, ELISA, ADCC assay

Purification: Purified by affinity chromatography with protein G

Quality control:

• The binding of Anti-hCD70 mAb to human CD70 on cells has been validated using flow cytometry.
• Isotype effector function has been validated using an ADCC cellular assay.
• The complete sequence of the antibody has been verified.
• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ hTLR2 and HEK-Blue™ TLR4 cellular assays.

Contents

Anti-hCD70-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

• hcd70-mab1: 100 µg
• hcd70-mab1-03: 3 x 100 µg

Product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20 °C.

Tags: buy Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) | Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) supplier | purchase Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) | Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) cost | Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) manufacturer | order Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) | Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) distributor

Details

The Cluster of Differentiation CD70 (aka CD27L, TNFSF7), a member of the TNFR family, is known as the sole ligand for CD27. The CD27–CD70 costimulatory receptor-ligand pair plays an important role in immune regulation. In concert with the T cell receptor (TCR) crosslinking, it promotes T cell activation, proliferation, survival, maturation of effector capacity, and T cell memory [1-2]. CD70 is primarily expressed on antigen-presenting cells (APCs) and upon interaction,with T cell-expressed CD27, it initiates the necessary signaling required for the proliferation and differentiation of antigen-specific T cells. Interestingly, it has been established that CD70 itself is transiently expressed on T cells after their activation. Evidence shows that T cell-expressed CD70 plays an important immune checkpoint role in the suppression of inflammatory T cell responses by a number of mechanisms including the upregulation of inhibitory immune checkpoint molecules [3]. Thus, the expression of CD70 on T cells has the ability to ameliorate inflammation and therefore, may be beneficial in the treatment of inflammatory diseases, such as inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) [3].

Constitutive overexpression of CD70 has been described in a range of solid and hematological malignancies, whereby tumor cells have hijacked the CD27-CD70 signaling pathway to facilitate immune evasion in the tumor microenvironment (TME) [4]. They do this by increasing the amount of suppressive regulatory T cells (Tregs), inducing caspase-dependent apoptosis of T cells, and skewing T cells towards exhaustion, to ensure they circumvent the immune response [1]. Additionally, the presence of CD70 on cancer stem cells has been shown to be a predictive marker for metastasis and poor prognosis [5]. Exploiting CD70-targeting in cancer patients has the potential to specifically eliminate the CD70-expressing cancer cell populations and abrogate the tumor-promoting mechanisms by the CD70-CD27 signaling axis, both in the early stage and advanced disease. Combinatorial approaches with anti-CD70 targeting therapies have proven their potential in both preclinical and clinical settings, using antibody-mediated therapy, chemotherapy, and Chimeric Antigen Receptor (CAR)-T cell therapy [6]. 

In conclusion, CD70 targeting agents like CD70-directed mAbs bear the potential of effectively targeting CD70-expressing solid and hematological tumors. Further clinical trials are needed to investigate potential combinations of immune-modulating therapies, especially at earlier stages of disease, to achieve the best possible outcome for cancer patients [7].

References:

1. Jacobs, J. et al. 2015. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther 155, 1-10.
2. Sanborn RE, et al., 2022 Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer. 2022 Aug;10(8):e005147.
3. O'Neill, R.E. et al. 2017. T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses. J Immunol 199, 3700-3710.
4. Jacobs, J. et al. 2018. Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. Oncoimmunology 7, e1440167.
5. Liu, L. et al. 2018. Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs. Breast Cancer 25, 706-716.
6. Flieswasser, T., Van den Eynde, A., Van Audenaerde, J. et al. 2022. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res 41, 12.
7. Starzer AM, Berghoff AS., 2020. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 4 (Suppl 3):e000629.